Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Aldeyra Therapeu (NQ: ALDX )

12.29 USD +0.50 (+4.24%)
Official Closing Price Updated: 7:59 PM EST, Jan 22, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Aldeyra Therapeu

< Previous 1 2 3 4 5 6 7 8 9 Next >
Thinking about buying stock in Aemetis, Aldeyra Therapeutics, Seelos Therapeutics, INmune Bio, or O2Micro International?
InvestorsObserver issues critical PriceWatch Alerts for AMTX, ALDX, SEEL, INMB, and OIIM. 
From PR Newswire
Aldeyra Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with... 
From Business Wire News Releases
Thinking about buying stock in Gevo, Applied DNA Sciences, Surface Oncology, Aldeyra Therapeutics, or BioNano Genomics?
InvestorsObserver issues critical PriceWatch Alerts for GEVO, APDN, SURF, ALDX, and BNGO. 
From PR Newswire
Thinking about buying stock in DBV Technologies, Endra Life Sciences, Precision BioSciences, Sorrento Therapeutics, or Aldeyra Therapeutics?
InvestorsObserver issues critical PriceWatch Alerts for DBVT, NDRA, DTIL, SRNE, and ALDX. 
From PR Newswire
Aldeyra Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with... 
From Business Wire News Releases
Aldeyra Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with... 
From Business Wire News Releases
Thinking about buying stock in T2 Biosystems, Zomedica, Aldeyra Therapeutics, La Jolla Pharmaceutical, or US Well Services?
InvestorsObserver issues critical PriceWatch Alerts for TTOO, ZOM, ALDX, LJPC, and USWS. 
From PR Newswire
Aldeyra Therapeutics to Participate in Fireside Chat at the H.C. Wainwright BioConnect 2021 Virtual Conference
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright... 
From Business Wire News Releases
Aldeyra Therapeutics Announces Positive Top-Line Symptom and Sign Results from Run-In Cohort of Phase 3 TRANQUILITY Trial in Dry Eye Disease
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced positive top-line symptom, redness, and Schirmer’s test results from the run-in cohort of the Phase 3 TRANQUILITY clinical trial in... 
From Business Wire News Releases
Aldeyra Therapeutics to Host Conference Call and Webcast to Discuss Top-Line Symptom, Redness, and Schirmer’s Test Results from Run-in Cohort of Phase 3 TRANQUILITY Trial
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call and webcast at 8:00 a.m. ET Thursday, January 7, 2021, to discuss top-line symptom, redness, and Schirmer’s test results... 
From Business Wire News Releases
Aldeyra Therapeutics Announces Confirmation of Antiviral Activity of ADX-1612
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced confirmation of SARS-CoV-2 antiviral activity of ADX-1612, in addition to novel anti-inflammatory activity in SARS-CoV-2-infected... 
From Business Wire News Releases
Aldeyra Therapeutics Announces Initiation of Phase 2 Clinical Trials of ADX-629, a First-in-Class Orally Administered RASP Inhibitor, for the Treatment of COVID-19, Atopic Asthma, and Psoriasis
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced the initiation of Phase 2 clinical trials of ADX-629, a first-in-class orally administered reactive aldehyde species (RASP)... 
From Business Wire News Releases
Aldeyra Announces First Patient Enrolled in the Phase 3 TRANQUILITY Trial of Reproxalap for the Treatment of Dry Eye Disease
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with... 
From Business Wire News Releases
Aldeyra Therapeutics to Participate in the Jefferies and A.G.P./Alliance Global Partners Virtual Investor Conferences
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the company’s senior management will participate in the following virtual investor conferences: 
From Business Wire News Releases
Aldeyra Therapeutics Announces Third-Quarter 2020 Financial Results and Provides Corporate Update
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with... 
From Business Wire News Releases
Aldeyra to Participate in the American Academy of Ophthalmology Eyecelerator 2020 Virtual Conference on Friday, November 6
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that President and CEO Todd C. Brady, M.D., Ph.D., will discuss Aldeyra’s novel therapeutic approaches to treating anterior and... 
From Business Wire News Releases
Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Third-Quarter 2020 Financial Results and Corporate Update
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with... 
From Business Wire News Releases
Aldeyra to Present New Reproxalap Data from Phase 2 Clinical Trial in Allergic Conjunctivitis at American Academy of Ophthalmology 2020 Annual Meeting
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that it will present new data from the Phase 2 allergen chamber clinical trial of reproxalap ophthalmic solution (0.25% and 0.5%) in... 
From Business Wire News Releases
Aldeyra to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that President and CEO Todd C. Brady, M.D., Ph.D., Chief Financial Officer Joshua Reed, and Chief Commercial Officer David McMullin... 
From Business Wire News Releases
Aldeyra to Present at Cantor and H.C. Wainwright Virtual Investor Conferences
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that senior management will be presenting and hosting one-on-one meetings at the following investor conferences: 
From Business Wire News Releases
Aldeyra Receives Study May Proceed Letter from FDA to Initiate Clinical Trial of ADX-629 in COVID-19 Patients
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that it has received a Study May Proceed letter from the U.S. Food and Drug Administration (FDA) to begin a Phase 2 clinical trial... 
From Business Wire News Releases
Aldeyra to Participate in Citi’s 15th Annual BioPharma Virtual Conference
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that President and Chief Executive Officer Todd C. Brady, M.D., Ph.D., will participate in an ophthalmology panel discussion during... 
From Business Wire News Releases
Thinking about buying stock in ADMA Biologics, Aldeyra Therapeutics Inc, Cancer Genetics Inc, Borqs Technologies, or Liminal BioSciences?
InvestorsObserver issues critical PriceWatch Alerts for ADMA, ALDX, CGIX, BRQS, and LMNL. 
From PR Newswire
Aldeyra Therapeutics Announces Second-Quarter 2020 Financial Results and Provides Corporate Update
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with... 
From Business Wire News Releases
Aldeyra Therapeutics to Participate in Upcoming Virtual Investor Conferences
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that senior management will be presenting and hosting 1x1 meetings at the following virtual investor conferences in August: 
From Business Wire News Releases
Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Second-Quarter 2020 Financial Results and Corporate Update
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with... 
From Business Wire News Releases
Aldeyra Therapeutics Announces Stock Sales to Perceptive Advisors and Avidity Partners
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today... 
From Business Wire News Releases
Aldeyra Therapeutics to Present at the OIS Virtual Public Company Showcase on July 16, 2020
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will discuss the company’s clinical programs in anterior and... 
From Business Wire News Releases
Aldeyra Therapeutics Announces New Drug Application (NDA) Development Plans for Dry Eye Disease
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with... 
From Business Wire News Releases
Aldeyra Therapeutics Receives Orphan Medicinal Product Designation from the European Commission for ADX-2191 Retinal Disease Program
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that ADX-2191 has been designated an orphan medicinal product by the European Commission for the treatment of retinal detachment.... 
From Business Wire News Releases
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.